XTX Topco’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-11,948
| Closed | -$346K | – | 4156 |
|
|
2025
Q4 | $346K | Buy |
+11,948
| New | +$227K | 0.01% | 1947 |
|
|
2025
Q1 | – | Sell |
-2,541
| Closed | -$90.8K | – | 2825 |
|
|
2024
Q4 | $90.8K | Sell |
2,541
-11,349
| -82% | -$587K | 0.01% | 1786 |
|
|
2024
Q3 | $656K | Buy |
13,890
+9,033
| +186% | +$399K | 0.05% | 633 |
|
|
2024
Q2 | $244K | Buy |
4,857
+3,515
| +262% | +$254K | 0.02% | 1091 |
|
|
2024
Q1 | $150K | Buy |
+1,342
| New | +$133K | 0.02% | 1262 |
|
|
2023
Q4 | – | Sell |
-3,169
| Closed | -$101K | – | 1912 |
|
|
2023
Q3 | $101K | Buy |
+3,169
| New | +$151K | 0.02% | 1183 |
|
|
2023
Q2 | – | Sell |
-1,830
| Closed | -$188K | – | 1666 |
|
|
2023
Q1 | $188K | Sell |
1,830
-3,486
| -66% | -$489K | 0.04% | 977 |
|
|
2022
Q4 | $779K | Buy |
5,316
+2,782
| +110% | +$470K | 0.17% | 140 |
|
|
2022
Q3 | $428K | Buy |
2,534
+985
| +64% | +$160K | 0.11% | 305 |
|
|
2022
Q2 | $179K | Buy |
1,549
+1,146
| +284% | +$108K | 0.07% | 495 |
|
|
2022
Q1 | $40K | Sell |
403
-63
| -14% | -$7.36K | 0.02% | 608 |
|
|
2021
Q4 | $72K | Buy |
+466
| New | +$90.7K | 0.04% | 520 |
|
|
2021
Q3 | – | Sell |
-582
| Closed | -$197K | – | 927 |
|
|
2021
Q2 | $197K | Buy |
+582
| New | +$220K | 0.07% | 570 |
|
Other funds holding MRSN
XTX Topco's MRSN Position: Q1 2026 in Review
XTX Topco sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 11,948 shares — an estimated $346K sold.
XTX Topco first reported a position in MRSN in Q2 2021 and held it in 13 quarters. The position peaked at $779K in Q4 2022. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.
- XTX Topco reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
- XTX Topco sold 11,948 Mersana Therapeutics shares in Q1 2026, an estimated $346K.
- XTX Topco first reported a position in Mersana Therapeutics in Q2 2021 and held it in 13 quarters.
- XTX Topco's Mersana Therapeutics position peaked at $779K in Q4 2022.
- 1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.
Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.